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Summary 
The activity of the human erythrocyte acid phosphatase is modulated by a series of structural analogs of 
purine. The unsubstituted purine base does not affect the enzyme activity. Addition of a substituent at the 
number six position usually generates an analog which activates the enzyme while similar substitutions at the 
two position usually generate an inhibitor. Pyrimidines are generally ineffective as modulators while several 
modifications of the imidazole ring of the purine analogs do not abolish the modulator  activity of the purine 
analog. The level of response to all active analogs is isozyme specific. Differences in apparent  relative 
affinities among the modulators  are noted. The modulators  with a positive effect on enzyme activity, are 
effective in the presence of methanol which is more effective than H20 as a phosphate acceptor. These analogs 
act by enhancing the rate of transfer of phosphate to H20, while decreasing the rate of transfer to methanol. 
The results suggest that the purine analogs may act by altering the rate of hydrolysis of the phosphoenzyme 
intermediate by H 2 0  or  may change the rate-limiting step in the catalytic mechanism. 
Introduction 
Human erythrocyte acid phosphatase (ACP, EC 
3.1.3.2) is a monomeric enzyme of approximately 
12 14000 dalton molecular weight (1). Three 
common alleles ACPj A, ACP1B and ACPj c are 
observed in human populations. These isozymes 
differ in electrophoretic mobility, level of activity 
and thermostability (2 7). Another characteristic 
of the erythrocyte ACP isozymes is the modulation 
of enzymatic activity by a series of purine analogs 
(5, 6, 8-10). The response is observed as either 
enhancement or inhibition of the rate of product 
formation. The direction of the modulation is a 
specific function of the purine analog; each analog 
is either an activator or an inhibitor irrespective of 
the isozyme being studied. In contrast, the relative 
extent of the modulation is a function of the iso- 
zyme structure with the order of response being 
ACP-C: ACP-A: ACP-B. The C isozyme may be 
either the least or most responsive but it will always 
be at the opposite extreme from the B isozyme with 
the A isozyme and the various heterozygote combi- 
nations exhibiting intermediate levels of response. 
A similar consistent ordering of response is ob- 
served in studies of the purine modulation of ery- 
throcyte ACP from other species (11). Thus, the 
absolute level of modulation is a function of the 
interaction of specific features of the purine analogs 
with binding sites on the ACP molecule. This inter- 
action is sensitive to both the structure of the en- 
zyme and the purine analog as reflected in the speci- 
ficity of response noted among the allelic variants in 
the human population (5, 6, 8, 9) as well as among 
the isozymes from several species (11). 
A low molecular weight ACP with many charac- 
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teristics similar to the erythrocyte ACP has been 
identified in several tissues (12-18). The activity of 
the low molecular weight ACP from human liver 
( l l )  and placenta (19) and bovine liver (11) and 
brain (20) is also modulated by several purine anal- 
ogs. 
The catalytic mechanism of the ACP enzyme is 
proposed to involve a phosphoenzyme interme- 
diate, with the rate-limiting step being transfer of 
the phosphate from the enzyme to an acceptor (21, 
22). This would explain the rate enhancement ob- 
served when, in addition to H20, alcohols which are 
better acceptors than H20, are present as the accep- 
tot in the assay (5, 7, 20). The mechanism for the 
purine modulation, which exhibits uncompetitive 
kinetics (8, 20, 21), is unclear although the data are 
consistent with facilitation of removal of the phos- 
phate group from the enzyme (20). The mechanism 
does not involve either transphosphorylation to 
modulator or covalent binding of modulator to the 
enzyme (20). 
This paper will report on some additional struc- 
tural features of the purine analogs required for 
modulation of the activity of the human erythro- 
cyte acid phosphatase. The interaction between 
pairs of modulators as well as modulators and al- 
cohol will also be reported. 
Materials and methods 
Blood samples were collected, washed and stored 
as described by Fielek and Mohrenweiser (23). 
Hemolysates for electrophoresis were prepared as 
decribed by Mohrenweiser and Novotny (6). Verti- 
cal starch gel electrophoresis was utilized to con- 
firm the ACP phenotypes (24). Hemolysates for 
activity studies were prepared and dialyzed as de- 
scribed by Yoshihara and Mohrenweiser (5). 
ACP activity, with p-nitrophenyl phosphate 
(p-NPP) as substrate, was assayed as described by 
Mohrenweiser and Novotny (6) except that the 
buffer was 0.1 M sodium acetate, adjusted to pH 5.5 
with HC1 and the substrate concentration was 
10 mM. The incubation time was 10 mih at 37 ° C. 
The extent of transphosphorylation to methanol 
was estimated by measuring p-nitrophenoxide 
(p-NP) and phosphate (Pi) from the same reaction 
tube and the methylphosphate was calculated as the 
difference as done by Tanizaki et al. (20). The phos- 
phate assay used was that of Lanzetta et al. (25). All 
assays were done in duplicate and samples from two 
individuals of each phenotype were used. The varia- 
tion among individuals and/or  replicates was less 
than 5%. The rate of product formation was linear 
with time for all assay conditions employed. 
All purine and pyrimidine analogs, as well as 
p-nitrophenyl phosphate, were obtained from Sig- 
ma Chem. Co. and used without further purifica- 
tion. 
Results 
Structural specS'city for modulation 
The data on the effect of various purine analogs 
on ACP activity are summarized in Table 1. As in 
most previous studies, the B-type isozyme (the most 
common variant in human populations) was 
used for initial studies. Enzyme from heterozygous 
ACPI Ac type individuals was also used for further 
studies, which confirmed previous observations 
that the extent but not the direction of modulation 
is isozyme specific. The unsubstituted purine base is 
ineffective as a modulator of human erythrocyte 
ACP activity. Addition of a substituent at the 
number 6-position of the purine base, with the ex- 
ception of a chlorine atom, gefierates a series of 
activators which enhance the rate of product for- 
mation by up to 4-fold. Isozyme specificity is ob- 
served, with the BB phenotype being most respon- 
sive to the addition of the -OH and -SH adducts 
while the two amino derivatives, -NH 2 and -N- 
(CH3) 2 are the better enhancers of the activity of the 
AC phenotype. Replacement of the -SH by the 
larger -S-CH2-CH 3 adduct reverses the genotype 
specificity and the level of enhancement by the 
analog with the larger adduct is reduced. 
Addition of an amino group at the 2-position 
instead of the 6-position of the base generates an 
inhibitor instead of an activator. The addition of 
the -OH or -SH group to the 2-position of the 
purine base is without significant effect, relative to 
the unsubstituted base but this ineffectiveness is in 
contrast to the positive modulation observed when 
these groups were at the 6-position. 
The 2,6-disubstituted purine bases are either ac- 
tivators or inhibitors, depending upon the adducts. 
With the exception of the 6-NH 2 derivative, all of 
Table 1. Modulation of ACP activity by a series of purine analogs. 
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Compound Structure Activity 
2 a 6 Ring b BB AC 
purine X X PU 93 100 
6-hydroxy purine (hypoxanthine) X OH PU 203 144 
6-mercapto purine X SH PU 292 170 
6-amino purine (adenine) X NH PU 131 225 
6-chloro purine X CI PU 81 83 
6-dimethylamino purine X N--(CH3)2 PU 387 589 
6-ethylmercapto purine X S-CH2CH3 PU 143 211 
2-hydroxy purine OH X PU 100 118 
2-mercapto purine SH X PU 78 92 
2-amino purine NH X PU 47 60 
2-hydroxy-6-thio purine OH SH PU 190 145 
2-hydroxy-6-amino purine (isoquanine) OH NH PU 77 70 
2-hydroxy-6-methyl purine OH CH PU 112 143 
2-thio-6-hydroxy purine S H OH PU 90 86 
2,6-dihydroxy purine (xanthine) OH OH PU 116 121 
2-amino-6-hydroxy purine (guanine) NH OH PU 62 68 
2-amino-6-mercapto purine NH SH PU 90 78 
2,6-diamino purine NH NH PU 25 31 
uric acid OH OH PU 85 70 
adenosine X NH PU-R 97 102 
inosine X OH PU-R 164 233 
guanosine NH OH PU-R 208 325 
6-mercaptoguanosine N H S H PU-R 178 200 
6-chloroguanosine NH CI PU-R 99 99 
7-methylguanosine NH OH PU-R 85 83 
l-methylguanosine N H OH P U-R 99 101 
allopurinol X OH ALP 215 171 
hydroxypteridine X OH PT 100 100 
lumazine OH OH PT 96 107 
folic acid NH OH PT 46 25 
xanthopterin O H N H PT 76 65 
All of the compounds were present at a concentration of 5.0 mM except for guanine, isoguanine, and folic acid at 1.0 mM and xanthine, 
dimethylamino purine and uric acid at 2.5 mM. Activity is expressed as percent of activity in the absence of purine analog. The responses 
of both the BB and AC isozymes were studied. 
Substituent at the 2- and/or 6-position of the purine. X indicates no adduct present. 
b The basic ring structures are as follows: PU - purine; PUR purine riboside; ALP pyrazolopyrimidine; PT - pteridine. 
t he  2 - O H  a n a l o g s  a re  a c t i v a t o r s ,  a l t h o u g h  t he  ex-  
t e n t  o f  a c t i v a t i o n  is n o t  o f  t he  m a g n i t u d e  o b s e r v e d  
w i t h  t he  6 s u b s t i t u t e d  a n a l o g s .  T h e  i n t e r c h a n g e  o f  
t h e  - O H  a n d  - S H  g r o u p s ,  f r o m  the  2 - O H ,  6 - S H  to  
the  2 - S H ,  6 - O H  c o n f i g u r a t i o n ,  c h a n g e s  t he  p u r i n e  
a n a l o g  f r o m  a g o o d  a c t i v a t o r  to  a r e l a t i ve ly  i n a c t i v e  
c o m p o u n d .  A n  - N H  2 g r o u p  a t  the  2 - p o s i t i o n ,  in  
c o n j u n c t i o n  w i t h  a n y  s u b s t i t u e n t  a t  t h e  6 - p o s i t i o n ,  
r e su l t s  in  a n e g a t i v e  m o d u l a t o r ,  w i t h  t he  2 , 6 - d i a m i -  
n o  a n a l o g  b e i n g  a p o t e n t  i n h i b i t o r .  A d d i t i o n s  a t  
o t h e r  p o s i t i o n s ,  in a d d i t i o n  to  the  2- a n d  6 -pos i -  
t i ons ,  u s u a l l y  r e su l t s  in  a r e l a t i ve ly  i ne f f ec t i ve  m o d -  
u l a t o r ,  w i t h  o n l y  ur ic  ac id  e x h i b i t i n g  s i g n i f i c a n t  
( i n h i b i t o r y )  ac t iv i ty .  T h e o p h y l l i n e ,  t h e o b r o m i n e  
a n d  c a f f e i n e  were  al l  w i t h o u t  s i g n i f i c a n t  m o d u l a t o r  
ac t iv i ty .  
T h e  a d d i t i o n  o f  t he  r i b o s e  m o i e t y  to the  p u r i n e  
ba se  ha s  a s i g n i f i c a n t  e f fec t  o n  the  f u n c t i o n a l i t y  o f  
t he  v a r i o u s  a n a l o g s .  T h e  6 - N H z - s u b s t i t u t e d  p u r i n e  
( a d e n i n e )  is a g o o d  a c t i v i t o r  of  A C P  ac t iv i ty ,  whi le  
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the 6-NH2-substituted nucleoside (adenosine) is in- 
effective as a modulator. Both of the 6-OH-substi- 
tuted analogs are activators but the BB isozyme is 
most responsive to the purine base (hypoxanthine) 
while the AC isozyme is activated to a greater ex- 
tent by the nucleoside (inosine). The 2-NH2, 6-OH- 
substituted purine (guanine) is an inhibitor. How- 
ever, the corresponding nucleoside (guanosine) 
activates the BB and AC isoenzymes 2- and 3-fold 
respectively. The 6-SH derivative of guanosine is 
less effective than guanosine as an activator and 
substitution of a chloro group for the -OH at the 
6-position generates an analog which is inactive. 
Also, addition of a methyl group at either the 
number 1 or 7 nitrogen of guanosine results in an 
inactive analog. Guanosine and mercaptoguano- 
sine were unique in being the only 2-amino-substi- 
tuted compounds which were positive modulators 
of ACP activity. 
It seems clear that additions to the pyrimidinyl 
ring have a key role in the modulation of ACP 
activity by purine analogs. It is equally clear that 
the functional mechanism must require a 'purine- 
like' ring structure in that a series of pyrimidine 
analogs are, at most, minimally effective in modu- 
lating ACP activity. The pyrimidines, cytosine, 
2-aminopyrimidine, 2-hydroxypyrimidine 2-thio, 
4-amino-6-hydroxypyrimidine, 2-mercaptopyrimi- 
dine and alloxan, have no significant modulating 
effect on ACP activity. Only the 2-hydroxy-substi- 
tuted compound, isocytosine, has any modulating 
effect being a weak inhibitor of both isozymes (77 
and 63% of control for BB and AC respectively). 
The replacement of the imidazole ring with a 
pyrazole ring seems to have minimal effect, as allo- 
purinol has a modulating effect which is very sim- 
ilar to that observed for hypoxanthine. Substitu-" 
tion ofa pyrazine ring, for the imidazole ring also is 
without significant effect for three analogs, al- 
though two are inhibitors and the third is inactive. 
Lumazine (inactive), folic acid (inhibitor), and xan- 
thopterin (inhibitor) have modulator activities 
quite similar to the appropriate purine analogs. The 
exception is the activator, hypoxanthine as the pyr- 
azine analog, 4-hydroxyteridine is ineffective as a 
modulator. Addition of a methyl group at the 7- 
nitrogen of the imidazole ring (7-methyl guanosine) 
results in the loss of activation capability while 
addition of a hydroxyl group at carbon 8 (uric acid) 
creates an analog which is an inhibitor rather than a 
weak activator (xanthine). 
Analog combinations 
The modulation of ACP activity by combina- 
tions of analogs was investigated in several series of 
experiments. In the first experiment, pairs of modu- 
lators were mixed in ratios to maintain a constant 
combined concentration of modulators. Two types 
of results were observed. The first was that ob- 
served with the combination of the activator, 6- 
aminopurine (adenine) and the inhibitor, 2-amino- 
purine, where the activity observed in the presence 
of both modulators was simply the average of the 
two modulators alone. A similar response was seen 
when the two activators - guanosine and 6-amino- 
purine, were used together. The response is that 
expected for 2 modulators competing equally for 
the same site. 
The second type of response was that observed 
with combinations which included folic acid. Equal 
molar concentrations of folic acid and either the 
activator, guanosine or the inhibitor, 2,6-diami- 
nopurine yielded the same response as observed 
with folic acid alone. In fact, folic acid at 0.25 mM 
concentration completely inhibited the activating 
capacity of 1.0 mM guanosine. In contrast, various 
ratios of guanosine and 2,6-diaminopurine pro- 
duced a level of modulation consistent with a sim- 
ple additive respone. 
These mixing experiments indicated a differen- 
tial or dominating effect of some modulators, thus 
the concentration dependence of the response to 5 
different compounds was examined. Due to the 
great differences in the levels of modulation pro- 
duced by the different analogs, the data are plotted 
as a percent of the maximum modulation observed 
for each compound for each isozyme. Figure 1A 
clearly indicates that the purine analogs fall into 
two groups, which differ greatly in their effective- 
ness as activators of ACP activity. Dimethylami- 
nopurine is maximally effective at approximately 
2 mM while guanosine and 6-mercaptopurine re- 
quire more than 6 mM effector for maximal activa- 
tion. Both genotypes respond in a similar manner to 
these activators. The inhibitors, in contrast, showed 
a phenotype-specific effect (Fig. 1B). The shape of 
the curve is phenotype dependent; the inhibition of 
the BB isozyme is greater, at lower effector concen- 
trations, for diaminopurine while the CC pheno- 
type is more sensitive to folic acid inhibition. The 
differences in response are approximately 2-fold at 
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Fig. 1. Concentration dependence of modulation. Activity is expressed as percent of maximum response. ( - - )  BB phenotype; (--) CC 
phenotype; A. (=) dimethylaminopurine; (A) 6-mercaptopurine; (e) guanosine; B. (A) folic acid; (o) 2,6-diaminopurine. 
In an additional series of experiments, several 
inactive purine analogs were mixed with the activa- 
tor, guanosine. The concentration of the inactive 
analogs were held constant at 1 mM while the con- 
centration of guanosine was varied from 0.25 to 1.0 
mM. Two types of results could be expected from 
this series. If the inactive analog binds to the en- 
zyme molecule at the same site as the activator, it 
would reduce the binding of the activator and there- 
by reduce the modulation observed. If, on the other 
hand, the inactive analog does not bind to the en- 
zyme, then no deviation from the level of modula- 
tion by guanosine alone would be expected. Both of 
these results were observed. 4-hydroxypteridine, 
and to a lesser degree l-methylguanosine, clearly 
reduced (15 25%) the activation observed with 
guanosine alone. Adenosine and 2-hydroxypyrimi- 
dine had no effect, i.e., they did not seem to bind to 
the enzyme. When 4-hydroxypteridine was mixed 
with guanosine so as to maintain a constant concen- 
tration of purine analogs, the resulting respose was 
again that expected for two modulators competing 
for the same site. This is further evidence that this 
inactive analog is competing for the modulator site 
on the enzyme but is unable to enhance (or inhibit) 
the rate of catalysis. 
Analog-methanol interaction 
The rate of product (p-nitrophenoxide) forma- 
tion is also enhanced by the addition of alcohol to 
the reaction mix, the enhancement being via a 
transphosphorylation mechanism (20). Thus, we 
examined the interaction of methanol plus a series 
of modulators. 
The degree to which various modulators affect 
the rate of product (p-NP) formation in the absence 
and presence of methanol is summarized in Table 2. 
Guanosine and 6-dimethylaminopurine enhance 
the rate of product formation, for both the BB and 
AC phenotypes, above that observed with meth- 
anol alone; 6-mercaptopurine shows the enhance- 
ment effect for the BB, but not for the AC isozymes. 
Adenine and hypoxanthine show no enhancement 
and, in fact, they inhibit the rate of product forma- 
tion, relative to the rate with methanol alone for the 
lesser responsive isozyme. This latter rate is above 
the rate observed when the assay is conducted with 
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without meth- without meth- 
meth- anol meth- anol 
anol anol 
Control 100 278 100 277 
6-dimethylaminopurine 406 478 653 654 
6-mercaptopurine 278 343 191 258 
Guanosine 189 319 305 377 
Hypoxanthine 153 279 130 247 
Adenine 131 200 197 263 
2,6-diaminopurine 29 61 38 97 
Folic acid (1.0 mM) 50 130 33 70 
Folic acid (0.1 mM) 67 150 47 95 
Methanol was present as 10% of the reaction volume while all 
purine analogs were present at a concentration of 2.5 mM except 
for folic acid which was at 1.0 mM and 0.1 mM. Assays were as 
described in'Methods' and activity is expressed as percent of the 
activity in absence of either methanol or analog for each geno- 
type. The responses of both the BB and AC isozymes were 
studied. 
modu la to r  but wi thout  methanol .  The enhance-  
ment  effect of guanosine,  observed in the presence 
of methanol ,  is e l iminated as the methanol  concen- 
t ra t ion  in the assay system is increased to 30% 
methanol.  
The two inhibitors,  folic acid and diaminopurine,  
reduce the rate of product  fo rmat ion  to 25-50% of 
that  observed with methanol  alone. The rate of  
transfer of  phosphate  to H20  in the presence of 
either inhibi tor  is not  al tered by the addi t ion of 
methanol .  Thus, the relative effectiveness of  the 
inhibitors is not  significantly altered by the addi t ion 
of 10% methanol .  
In order  to investigate the methanol  enhance- 
ment  effect further,  the response of several addi- 
t ional isozymes of human ACP,  to incubat ion with 
ac t iva tor  plus methanol ,  was examined (Table 3). 
Enhancemen t  of  the rate by guanosine  in the pres- 
ence of 10% methanol  is observed for all genotypes 
with the greatest effect being shown by those geno- 
types which are most  responsive to guanosine. The 
analog 6-mercaptopur ine  is a less effective act ivator  
and two different  responses are observed when the 
react ion rate is measured in the presence of meth- 
anol. With  the more responsive isozymes, BB and 
AA,  6 -mercap topur ine  enhances (20 and 10% re- 
Table 3. Effect of methanol on the modulating effect of guano- 
sine and 6-mercaptopurine for five ACP phenotypes. 
Treatment ACP phenotypes 








100 100 100 100 
276 265 266 259 
220 266 293 328 
335 347 366 375 
246 189 182 147 
307 245 247 214 
Methanol was present as 10% of the reaction volume and purines 
at a concentration of 2.5 raM. Assays were conducted as de- 
scribed in 'Methods'. Activity is expressed as the percent of 
activity in the absence of modulator and methanol, for each 
isozyme. 
spectively) the rate above that  observed with me- 
thanol  alone. The addi t ion  of  the analog results in a 
reduct ion to only 80% of the rate for methanol  
alone for the least responsive isozyme (CC). The 
data  suggest a threshold for responsiveness,  with a 
m o d u l a t o r  required to enhance the react ion rate, in 
the absence of methanol ,  some 1.8-2.0-fold before 
it elicits a posit ive response in the presence of  10% 
methanol .  
Produc t  f o r m a t i o n  
With reactions conducted  in the presence of me- 
thanol and H20 , the phosphate  can be transferred 
to either acceptor  (20). The effect of  several modu-  
lators on the dis t r ibut ion of products  is summar-  
ized in Table  4. The addi t ion  of  10% methanol  to 
the assay enhances the react ion rate some 2.5-2.8 
times. The  methy lphospha te  to phosphate  ratio is 
approx imate ly  2:1 for both phenotypes.  The addi- 
t ion of any of  the four  analogs which enhance A C P  
activity results in an increased rate of  phosphate  
transfer to H20 and a decrease in the rate of transfer 
to methanol  when the react ion is conducted in the 
presence of  both methanol  and analog. The net 
effect on the total  react ion rate is dependent  upon 
the relative changes (which are in opposite  direc- 
tions) in each reaction. For  example,  the addi t ion 
of  d imethy laminopur ine  is associated with a 
25-50% decrease in the amoun t  of methylphos-  
phate formed and a 3 5-fold increase in the transfer 
to H20. Guanos ine  addi t ion is associated with only 
Table 4. Distribution of reaction products in the presence and absence of methanol for six modulators of ACP activity. 
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Distribution of products 
BB AC 
P-NPa Pi Me-P P-NP Pi Me-P 
1. Control 36 a 36 38 38 
2. Methanol 102 33 69 101 34 65 
3.6-dimethyla minopurine 126 126 - 208 204 
4.6-DMAP plus methanol 153 104 49 211 182 29 
5. Guanosine 74 76 122 115 - 
6. Guanosine plus methanol 122 58 64 143 85 58 
7.6-mercaptopurine 109 104 - 75 73 - 
8.6-MP plus methanol 131 85 46 96 60 36 
9. Adenine 47 46 - 74 75 - 
10. Adenine plus methanol 72 41 31 99 62 37 
11 2,6-diaminopurine 10 l0 15 15 - 
12.2,6-DAP plus methanol 22 10 12 35 15 20 
13. Folic acid 24 17 18 12 
14. Folic acid plus methanol 54 16 38 36 11 25 
All assays were conducted as described in' Methods'. The methanol concentration was 10%. The concentration of purine analog was 2.5 
mM except for folic acid which was at 0.1 raM. The responses of both the BB and A isozymes were studied, p-nitrophenoxide and 
phosphate concentrations were measured directly and the methylphosphate was determined by the difference, p-NP = p-nitrophenoxide, 
Pi - phosphate, Me-P - methyl-phosphate. 
a #Mole product formed/l0 min. 
a doubl ing  of the transfer  to H20  and the decrease 
in methy lphospha te  fo rma t ion  is only 10%. The net 
result for  both  analogs is an enhancemen t  of  the 
rate of  react ion relative to reactions with methanol  
but wi thout  analog.  By contrast ,  adenine has a 
significant negative effect on the rate of  methyl-  
phosphate  produc t ion  and only minimal  enhancing 
effect on the transfer  to H20.  Thus,  the net effect of  
adenine addi t ion,  relative to methanol  alone, is a 
decreased rate of react ion for the BB isozyme. The 
relative changes are equal  for the AC isozyme with 
the net  effect being zero. In all assays, the addi t ion 
of modu la to r  changed the product  dis t r ibut ion 
f rom that  observed with methanol  alone, reflecting 
the increased transfer  to H20 with at least a margi- 
nal decrease in the a m o u n t  of  methy lphospha te  
produced.  This a l tera t ion in product  ratio included 
the several combina t ions  where the overall  react ion 
rate for methanol  plus ac t iva tor  was equal  to or less 
than the rate with methanol  alone. The amount  of  
phospha te  produced  never at ta ined the level ob- 
served when the assays were conducted  with activa- 
tor  but wi thout  methanol ,  but it was always greater  
than the level produced wi thout  activator.  
The methanol -enhanced  rate observed for assays 
conducted  with folic acid or d iaminopur ine  is ac- 
counted  for by the amoun t  of methy lphospha te  
formed wi thout  any increase in the amoun t  of 
phosphate  transfered to H20. 
D i s c u s s i o n  
The activity of erythrocyte  A C P ,  either in dia- 
lyzed hemolys ta te  or as purified preparat ions ,  is 
modula ted  by purine analogs (8, 9). Purine analog 
modula t ion  of a purified or partially purified low 
molecular  weight tissue enzyme is also observed 
(11, 20). Most  data  suggest the erythrocyte  and 
tissue A C P  are the same enzyme (12, 18) a l though 
some differences in propert ies  have been repor ted  
(14). The specific mechanism by which an extensive 
series of purine analogs modula te  the activity of this 
small, monomer i c  enzyme is not clearly under-  
stood. The enhancement  of  activity via an uncom-  
petit ive mechanism (3, 20) implies the existence of a 
second site. Studies of this effect with the low mo- 
lecular weight tissue ACP,  are consistent with a role 
at the catalytic step involving removal  of phosphate  
f rom the enzyme (20), which is the rate-l imiting step 
(21,22). The ability of several analogs to modify  the 
enhancing  activity of  other  analogs,  wi thout  them- 
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selves being modulators indicates that the binding 
of modulator is independent of modulator influ- 
ence on catalysis. It is also clear that some modula- 
tors are maximally active at much lower concentra- 
tions than others and when mixed with modulators 
with lower affinity exert a dominant effect. This 
suggests that modulators bind with different affini- 
ties. The extent of the response to each modulator is 
genotype specific indicating that the amino acid(s) 
which differ between the isozymes must be in- 
volved, directly or indirectly, with the modulation 
site (or mechanism). No examples of modulators 
being inhibitors of one isozyme and an activator of 
another have been observed. 
Enough differences in response to structurally 
similar analogs are observed to preclude defining 
absolute requirements for modulation, although 
several generalizations are possible. It is necessary 
for the purine base to be substituted at the 6-posi- 
tion for substantial positive modulation. The ad- 
duct can be quite large and still be a good activator, 
e.g. dimethylamino or mercaptoethyl groups, al- 
though the chloro adduct is an inhibitor. Adducts 
at the 2-position, in contrast to similar adducts at 
the 6-position, tend to be either inactive or inhibi- 
tots. The disubstituted analogs are generally inter- 
mediate in modulating activity, although all of the 
2-amino analogs become inhibitors with the diami- 
no analog being a strong inhibitor. Addition of the 
ribose moiety confuses the generalization in that 
the 6-amino substituted analog (adenosine) is no 
longer an activator while the 2-amino, 6-hydroxyl 
analog (guanosine) is a strong activator rather than 
an inhibitor and the phenotype specificity of the 
6-hydroxyl analog(inosine) is reversed. Interesting- 
ly, addition of a methyl group to either the 1- or 
7-nitrogen obliterates the positive modulation ca- 
pabilities of guanosine. 
A bicyclic ring structure appears important as the 
pyrimidines are generally ineffective as modulators. 
Increasing the ring size by one carbon atom (pteri- 
dine) or creating a pyrazole ring (allopurinol) al- 
tered the modulation characteristics for only one of 
five comparisons. 
The analog specificities observed with the ery- 
throcyte enzyme are not inconsistent with the pre- 
vious results from studies with isozyme III from 
human placenta (19), although the generally low 
level of response in the studies of the placental 
enzyme make significant comparisons difficult. A 
partially purified human liver low molecular weight 
ACP have modulation characteristics similar to 
those observed for the erythrocyte enzyme (ll).  
Significant differences with the results reported for 
the low molecular weight ACP from bovine brain 
are evident (20). These include the activation of the 
brain isozyme by guanine rather than inhibition as 
observed with the human erythrocyte isozymes. 
Additionally, the bovine brain isozyme was un- 
responsive to hypoxanthanine, an activator of the 
human isozymes. In contrast to the brain enzyme, 
both the bovine erythrocyte and liver enzyme ex- 
hibits responses similar to those observed for the 
human enzyme (11). It is possible that the differen- 
ces reflect tissue specificity. 
The addition of methanol as a potential phos- 
phate acceptor results in an increased rate of cataly- 
sis. Addition of the purine analogs (activators), in 
addition to methanol, has two consequences. The 
analogs not only increase the amount of phosphate 
produced relative to no activator or methanol, but 
also cause a decrease in the amount of methylphos- 
phate produced relative to methanol alone. Thus 
the net effect on the total reaction rate reflects the 
sum of the increased rate of phosphate transfer to 
H20 and the decreased rate of transfer to alcohol. 
The mechanism for the apparent thresholding, that 
is, the observation that the modulator must en- 
hance enzyme activity to a level approximately 1.8 
times the control activity before it enhances the 
activity in the presence of 10% methanol is not 
immediately evident. Obviously it could involve 
conformational changes and the relative position of 
the amino acid residue(s) important for the de- 
phosphorylation (transphosphorylation) step. 
Under the conditions of these experiments (saturat- 
ing substrate and modulator, assayed at pH 5.5) it is 
clear that modulators enhance the transfer of phos- 
phate to H20 relative to alcohol. This is observed 
when the modulator is inhibiting the total reaction 
rate in the presence of alcohol, or enhancing the 
reaction rate. Thus the product ratio is a function of 
the presence of the modulator rather than the rate 
of the reaction. The data presented here are not 
inconsistent with the proposal of Tanizaki et al. (20) 
that purine analogs may change the rate liming 
step. The modulators could also act by enhancing 
the ability of H20 to act as an acceptor, relative to 
alcohol, while retaining the rate-limiting step. 
The potential physiological significance of the 
p u r i n e  a n a l o g  m o d u l a t i o n  of  A C P  ac t iv i ty  is un -  
c lear  fo r  severa l  r easons .  O n e  w o u l d  be the  a p p a r -  
en t  n o n - p h y s i o l o g i c a l  c o n c e n t r a t i o n s  o f  these  c o m -  
p o u n d s  n e c e s s a r y  fo r  s ign i f i can t  in vitro m o d u l a -  
t ion.  A n o t h e r  w o u l d  be the  lack o f  a w e l l - d e f i n e d  
f u n c t i o n  fo r  the  e n z y m e ,  a l t h o u g h  it is p r o p o s e d  to  
f u n c t i o n  as a f l av in  m o n o n u c l e o t i d e  p h o s p h a t a s e  
(8, 12). Severa l  A C P  p h e n o t y p e - d i s e a s e  a s soc i a -  
t i ons  have  been  r e p o r t e d  i n c l u d i n g  i nc r ea sed  sus-  
cep t ib i l i ty  to h e m o l y t i c  a n e m i a  a n d  j a u n d i c e  as well 
as low b i r t h  we igh t  a n d  p r e m a t u r e  b i r th  (26-31) .  
T h e  inve r se  r e l a t i o n s h i p  b e t w e e n  the level o f  ery-  
t h r o c y t e  A C P  ac t iv i ty  a n d  g l u t a t h i o n e  r e d u c t a s e  
ac t iv i ty  (16) sugges t s  a r e l a t i o n s h i p  b e t w e e n  A C P  
ac t iv i ty  a n d  e r y t h r o c y t e  f lav in  a d e n i n e  d i n u c l e o t i d e  
c o n c e n t r a t i o n  (32, 33) a n d  is c o n s i s t e n t  wi th  the  
p r o p o s e d  phys io log i ca l  f u n c t i o n  of  the enzyme .  
F u r t h e r  s tud ies  of  the  s t r u c t u r a l  d i f f e rences  
a m o n g  the  severa l  va r i an t s  o f  this  e n z y m e  s h o u l d  
p r o v i d e  ins igh t  i n to  the  m e c h a n i s m s  for  the  m o d u -  
l a t i on  a n d  pos s ib ly  be usefu l  in s tud ies  d i r ec t ed  
t o w a r d  f u r t h e r  d e f i n i t i o n  o f  the  phys io log i ca l  im-  
p o r t a n c e  of  this enzyme .  
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